Polypeptide compounds for inhibiting angiogenesis and tumor growth
AssigneeVasGene Therapeutics, Inc.
InventorsValery Krasnoperov, Sergey Zozulya, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill
Life of this patent
Estimating the term…
Abstract
In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
Claims45
An isolated antibody or antigen binding portion thereof that binds to an epitope situated in the extracellular portion of EphB4 and inhibits an EphB4 activity.
A hybridoma that produces an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, No. 079, No. 047, No. 057, No. 85H, No. 098, and No. 138.
24-29. (canceled)
31-32. (canceled)
An isolated antibody or antigen binding portion thereof that binds to an epitope situated within amino acids 327-427 or 428-537 of the EphB4 sequence of FIG. 1 and stimulates EphB4 kinase activity.
A hybridoma that produces an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, No. 079, No. 047, No. 057, No. 85H, No. 098, and No. 138.
42-47. (canceled)
49-50. (canceled)
An antibody that specifically binds to an epitope situated in the extracellular portion of EphB4, wherein the antibody is selected from the group consisting of Nos. 1, 23, 35, 47, 57, 79, 85L, 85H, 91, 98, 121, 131, and 138.
Dependencies are inferred from the claim text.